Glenvastatin
Alternative Names: Glenvastin; HOE 780; HR 780Latest Information Update: 08 Sep 1995
At a glance
- Originator Aventis
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 08 Sep 1995 Discontinued-II for Hyperlipidaemia in France (PO)
- 08 Sep 1995 Discontinued-II for Hyperlipidaemia in Germany (PO)
- 08 Sep 1995 Discontinued-II for Hyperlipidaemia in Japan (PO)